DM is the most common metabolic disorder worldwide and is a major risk factor for cardiovascular disease (CVD). Many risk factors
for CVD, including hyperglycemia, abnormal lipid profiles, and alterations in inflammatory mediators, are carried by type two diabetes
mellitus (T2DM) patients, a new adipocytokine, visfatin is associated with a wide range of biologic effects, including glucose
and lipid metabolism, and has been implicated in the pathogenesis of diabetes and obesity. Visfatin is an adipocytokine that was
identified in 2005. Visfatin has insulin mimetic effects; it binds to the insulin receptor at a different binding site than insulin and
activates it. The aim of this study was to investigate the effects of metformin or Glibenclamide alone or in combination on serum
visfatin levels, glycemic control, and lipid profile in TD2M patients. This study was carried out on type 2 diabetic patients with poor
glycemic control at the Specialized Center for Diabetes and Endocrinology, Al-Kindi Teaching Hospital, Baghdad. Results of this study
showed a significant reduction in serum visfatin concentration in different treated groups in comparison with newly diagnosed
diabetic group in addition to changes in glycemic and lipid profile among groups. The treatment with metformin a hypoglycemic
drug in T2DM is more effective in reducing serum visfatin level compared with other treatment regimen.

وصف الــ Tags لهذا الموضوع   TDM 2, visfatin, Glibenclamide, metformin, lipid profile.